[go: up one dir, main page]

MX9700552A - Conjugados de vitamina b12 y proteinas. - Google Patents

Conjugados de vitamina b12 y proteinas.

Info

Publication number
MX9700552A
MX9700552A MX9700552A MX9700552A MX9700552A MX 9700552 A MX9700552 A MX 9700552A MX 9700552 A MX9700552 A MX 9700552A MX 9700552 A MX9700552 A MX 9700552A MX 9700552 A MX9700552 A MX 9700552A
Authority
MX
Mexico
Prior art keywords
vitamin
administration
conjugates
proteins
delivery
Prior art date
Application number
MX9700552A
Other languages
English (en)
Inventor
Alan David Habberfield
Olaf Boris Kinstler
Colin Geoffrey Pitt
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX9700552A publication Critical patent/MX9700552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen las proteínas terapéuticamente utiles que están conjugadas a la vitamina B12 mediante enlace covalente en el sitio del carboxilo primario de la porcion de ribosa. Los conjugados resultantes son biologicamente activos y pueden ser formulados en composiciones farmacéuticas apropiadas para la distribucion de diversas rutas de administracion, preferentemente oral. La captacion en el intestino después de la distribucion oral es además mejorada por la co-administracion del factor intrínseco purificado.
MX9700552A 1994-07-29 1995-07-28 Conjugados de vitamina b12 y proteinas. MX9700552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/282,384 US5574018A (en) 1994-07-29 1994-07-29 Conjugates of vitamin B12 and proteins
PCT/US1995/009477 WO1996004016A1 (en) 1994-07-29 1995-07-28 Conjugates of vitamin b12 and proteins

Publications (1)

Publication Number Publication Date
MX9700552A true MX9700552A (es) 1997-05-31

Family

ID=23081275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700552A MX9700552A (es) 1994-07-29 1995-07-28 Conjugados de vitamina b12 y proteinas.

Country Status (6)

Country Link
US (1) US5574018A (es)
EP (1) EP0774976A1 (es)
JP (1) JPH09508141A (es)
CA (1) CA2195566A1 (es)
MX (1) MX9700552A (es)
WO (1) WO1996004016A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
EP0754189B1 (en) * 1994-04-08 2002-10-09 Receptagen Corporation Receptor modulating agents and methods relating thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
ES2244006T3 (es) 1996-08-27 2005-12-01 University Of Utah Research Foundation Bioconjugados y administracion de agentes bioactivos.
AU2003204343B2 (en) * 1998-06-12 2007-03-15 Access Pharmaceuticals Australia Pty Limited Vitamin B12 derivatives and methods for their preparation
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
US20010008627A1 (en) 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
CA2387757A1 (en) * 1999-10-15 2001-04-26 Henricus P. C. Hogenkamp Cobalamin conjugates useful as imaging agents and as antitumor agents
AU785505B2 (en) 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
RU2240826C2 (ru) 2000-02-03 2004-11-27 Эйсай Ко., Лтд. Ингибитор экспрессии интегрина
AU2001272935A1 (en) * 2000-05-31 2001-12-11 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as antibiotic agents and as imaging agents
WO2001092283A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as cardiovascular agents and as imaging agents
EP1334114A2 (en) * 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1754712A3 (en) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
GB2374010B (en) * 2001-02-26 2004-12-29 Council Scient Ind Res Novel vitamin B12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
CN1541106A (zh) * 2001-06-11 2004-10-27 转新疗法公司 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
US20030018009A1 (en) * 2001-06-20 2003-01-23 Collins Douglas A. Adenosyl-cobalamin fortified compositions
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
US20030144198A1 (en) * 2001-09-28 2003-07-31 Collins Douglas A. Coadministration of transport protein with conjugated cobalamin to deliver agents
WO2003030929A1 (en) * 2001-10-05 2003-04-17 Transition Therapeutics Inc. Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
WO2003072195A2 (en) * 2002-02-20 2003-09-04 Eli Lilly And Company Method for administering glp-1 molecules
KR100440725B1 (ko) * 2002-06-20 2004-07-15 주식회사 그린진 바이오텍 비생물성 스트레스에 대한 단자엽 식물의 내성을증가시키는 방법
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
ES2395082T3 (es) * 2003-01-27 2013-02-08 Endocyte, Inc. Conjugado de folato-vinblastina como medicamento
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20110092416A1 (en) * 2007-03-05 2011-04-21 Robert Patrick Doyle Vitamine B12 - Peptide Conjugates for Oral Delivery
EP2131855A2 (en) * 2007-03-05 2009-12-16 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US20100330161A1 (en) * 2009-06-29 2010-12-30 Syracuse University Technology Transfer And Industrial Development Office Oral delivery of tetanus toxoid
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
JP2016528299A (ja) * 2013-08-22 2016-09-15 ロバート・ドイルＲｏｂｅｒｔ ＤＯＹＬＥ ビタミンｂ１２および内因子を含む組成物およびその使用方法
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US10716827B2 (en) 2015-05-20 2020-07-21 Syracuse University Compositions and methods for enhancing peptide stability against protease digestion
US20180154007A1 (en) * 2015-05-20 2018-06-07 Syracuse University Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist
JP2019510031A (ja) * 2016-03-22 2019-04-11 バルケム コーポレイション コリン含有の組成物
GB202018713D0 (en) 2020-11-27 2021-01-13 Quadram Inst Bioscience Methods and compositions utilising vitamin b12 binding
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981863A (en) * 1975-02-25 1976-09-21 Micromedic Diagonistics, Inc. Cyanocobalamin derivatives
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
WO1990012095A1 (en) * 1989-04-03 1990-10-18 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
AU664365B2 (en) * 1991-04-02 1995-11-16 Access Pharmaceuticals Australia Pty Limited Oral delivery systems for microparticles
WO1994028015A1 (en) * 1993-05-20 1994-12-08 Biotech Australia Pty. Limited Lhrh antagonists
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0774976A1 (en) 1997-05-28
US5574018A (en) 1996-11-12
AU3201595A (en) 1996-03-04
WO1996004016A1 (en) 1996-02-15
AU683581B2 (en) 1997-11-13
JPH09508141A (ja) 1997-08-19
CA2195566A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
IL139285A0 (en) Peg-lhrh analog conjugates, their preparation and use
NO981436D0 (no) Farmasöytiske angiostatiske dipeptidsammensetninger og anvendelse derav
GEP20053473B (en) High Potency Dihydroergotamine Compositions
TR200002299T2 (tr) Epotilon kompozisyonları.
AR008378A1 (es) Conjudados de interferon
MX9700081A (es) Composiciones farmaceuticas de tacrina.
PH24313A (en) Emulsion composition for administration of sparingly water soluble ionizable hydrophobic drugs
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
FI890599A0 (fi) Antracyklin-immunokonjugater med ny linker och foerfarande foer deras producering.
AU2874099A (en) Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
MY118371A (en) Tetrahydrolipstatin containing compositions
GEP20022784B (en) Celecoxib Composition
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69231663D1 (de) Konjugate bestehend aus polysaccharid und protein
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
MXPA03011282A (es) Mezclas de conjugados de farmaco de hormona de crecimiento-oligomero que comprenden polialquilenglicol, uso de los mismos y metodos para su elaboracion.
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
MY113203A (en) Lyophilizate of lipid complex of water insoluble camptothecins
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
BR9611571B1 (pt) composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2403721A1 (en) Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor